JP2011529946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529946A5 JP2011529946A5 JP2011521575A JP2011521575A JP2011529946A5 JP 2011529946 A5 JP2011529946 A5 JP 2011529946A5 JP 2011521575 A JP2011521575 A JP 2011521575A JP 2011521575 A JP2011521575 A JP 2011521575A JP 2011529946 A5 JP2011529946 A5 JP 2011529946A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- active ingredient
- diameter
- growth factor
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 19
- 239000004480 active ingredient Substances 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 7
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 4
- 210000005003 heart tissue Anatomy 0.000 claims 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 3
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000008929 regeneration Effects 0.000 claims 3
- 238000011069 regeneration method Methods 0.000 claims 3
- 102100037597 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 claims 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 claims 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 2
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 2
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 2
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 2
- 102000036693 Thrombopoietin Human genes 0.000 claims 2
- 108010041111 Thrombopoietin Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229940116977 epidermal growth factor Drugs 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 229940053128 nerve growth factor Drugs 0.000 claims 2
- 229940032018 neurotrophin 3 Drugs 0.000 claims 2
- 229940097998 neurotrophin 4 Drugs 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 101710111489 Neurotrophin 1 Proteins 0.000 claims 1
- 102100037765 Periostin Human genes 0.000 claims 1
- 101710199268 Periostin Proteins 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 108010023082 activin A Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012798 spherical particle Substances 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0814302.6 | 2008-08-05 | ||
| GBGB0814302.6A GB0814302D0 (en) | 2008-08-05 | 2008-08-05 | Compounds and methods |
| PCT/EP2009/060171 WO2010015665A2 (en) | 2008-08-05 | 2009-08-05 | Compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529946A JP2011529946A (ja) | 2011-12-15 |
| JP2011529946A5 true JP2011529946A5 (cg-RX-API-DMAC7.html) | 2012-08-30 |
| JP5623400B2 JP5623400B2 (ja) | 2014-11-12 |
Family
ID=39846672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521575A Expired - Fee Related JP5623400B2 (ja) | 2008-08-05 | 2009-08-05 | 直径１０〜２０μｍのマイクロスフェアを含む非経口組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20120195939A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2323626B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5623400B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101639827B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102170868A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009279086B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0917571B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2732785C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2011000244A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2677005T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0814302D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011001261A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010015665A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| GB0814302D0 (en) | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
| US10195252B2 (en) | 2012-08-03 | 2019-02-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Recruitment of mensenchymal cells using controlled release systems |
| EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| EP2914273B1 (en) * | 2012-10-26 | 2018-07-04 | Cedars-Sinai Medical Center | Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration |
| EP2948543A1 (en) * | 2013-01-24 | 2015-12-02 | Bernardo Nadal-Ginard | Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof |
| ES2606636T3 (es) * | 2013-01-24 | 2017-03-24 | Pierre Fabre Médicament S.A.S. | Composición que comprende un antagomir encapsulado |
| EP4494699A3 (en) | 2014-10-03 | 2025-04-30 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| CN104650333B (zh) * | 2015-02-05 | 2016-08-24 | 浙江大学 | 聚乳酸/氢化聚丁二烯热塑性超分子弹性体及其制备方法 |
| PL3264997T3 (pl) | 2015-03-02 | 2019-07-31 | Accurate Medical Therapeutics Ltd. | Cewniki z otworami bocznymi do modyfikowania i podawania zawiesin pacjentowi |
| US10010400B2 (en) | 2015-03-30 | 2018-07-03 | Taris Biomedical Llc | Devices and methods for local delivery of drug to upper urinary tract |
| WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| JP6921116B2 (ja) | 2016-05-04 | 2021-08-18 | アキュレイト メディカル セラピューティクス リミテッド | スリットパターンを有する塞栓マイクロカテーテルヘッド |
| WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
| WO2017220615A1 (en) | 2016-06-20 | 2017-12-28 | Virbac | Method and apparatus for preparing a micro-particles composition |
| US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| JP7336769B2 (ja) | 2017-04-19 | 2023-09-01 | シーダーズ―シナイ メディカル センター | 骨格筋ジストロフィーを治療する方法及び組成物 |
| JP7364193B2 (ja) | 2017-11-02 | 2023-10-18 | アキュレイト メディカル セラピューティクス リミテッド | 内蔵フィルタを有する塞栓術用カテーテル |
| WO2019126068A1 (en) | 2017-12-20 | 2019-06-27 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| CN112203690A (zh) * | 2018-01-12 | 2021-01-08 | 哈佛大学校长及研究员协会 | 与具有粘附颗粒的巨噬细胞和/或单核细胞有关的组合物和方法 |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| WO2020234889A1 (en) | 2019-05-23 | 2020-11-26 | Accurate Medical Therapeutics Ltd. | Embolization catheter for reflux free delivery of microspheres |
| US20240082167A1 (en) * | 2021-01-22 | 2024-03-14 | University Of Connecticut | Synthetic artificial stem cells (sasc) |
| CN121099998A (zh) * | 2023-02-02 | 2025-12-09 | 银溪制药股份有限公司 | 使用igf-1嵌合蛋白的治疗方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| BR9510462A (pt) * | 1994-12-16 | 1998-12-15 | Andaris Ltd | Micropartículas reticuladas e seu uso como veículos terapéuticos |
| US5942253A (en) * | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
| CA2161863A1 (en) | 1995-10-31 | 1997-05-01 | Michael Vivian Sefton | Angiogenic material and uses thereof |
| US6511477B2 (en) | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
| JP2001524096A (ja) * | 1997-04-24 | 2001-11-27 | ニコムド イメージング エイエス | コントラスト剤を含む不溶性微粒子または小胞を使用する塞栓治療 |
| EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
| AU1384199A (en) | 1997-11-07 | 1999-05-31 | Chiron Corporation | Method for producing igf-1 sustained-release formulations |
| JP2002527401A (ja) | 1998-10-13 | 2002-08-27 | カイロン コーポレイション | Ｆｇｆの脈管形成的に有効な単位用量および投与方法 |
| CN1200693C (zh) | 1998-11-18 | 2005-05-11 | 佛罗里达大学 | 制备包衣药粒及药物制剂的方法 |
| US7651703B2 (en) | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| JPWO2003059375A1 (ja) * | 2002-01-17 | 2005-05-19 | 株式会社カルディオ | 組織再生複合療法 |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| AU2003272284B2 (en) * | 2002-09-05 | 2009-03-05 | Catherine G. Ambrose | Antibiotic microspheres for treatment of infections and osteomyelitis |
| US20070122487A1 (en) * | 2003-03-19 | 2007-05-31 | University Of Kentucky Research Foundation | (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres |
| ES2600554T3 (es) * | 2003-07-18 | 2017-02-09 | Oakwood Laboratories L.L.C. | Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas |
| US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| JP4532092B2 (ja) * | 2003-09-30 | 2010-08-25 | 泰彦 田畑 | 血管新生剤 |
| US20070116768A1 (en) | 2003-12-09 | 2007-05-24 | Michael Chorny | Sustained release preparations composed of biocompatible complex microparticles |
| JP5048323B2 (ja) * | 2004-03-31 | 2012-10-17 | 株式会社ツーセル | 損傷組織の治療剤と治療方法 |
| US7854944B2 (en) | 2004-12-17 | 2010-12-21 | Advanced Cardiovascular Systems, Inc. | Tissue regeneration |
| ES2273572B1 (es) * | 2005-05-04 | 2008-04-01 | Universidad De Sevilla | Procedimiento de preparacion de particulas de tamaño micro y nanometrico con productos labiles y particulas obtenidas. |
| WO2007028053A2 (en) | 2005-09-02 | 2007-03-08 | X-Cell Medical Incorporated | Methods of treating and preventing cardiac disorders |
| KR100718329B1 (ko) | 2005-09-08 | 2007-05-14 | 광주과학기술원 | 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법 |
| WO2007055561A1 (en) * | 2005-11-11 | 2007-05-18 | Vascular Biosciences | R-ras activity in vascular regulation |
| CN101563097A (zh) * | 2005-11-14 | 2009-10-21 | 企业合伙人风险资本公司 | 用于组织损伤的干细胞生长因子疗法 |
| CU23388B6 (es) | 2006-01-31 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
| PL2087890T3 (pl) | 2006-10-19 | 2014-08-29 | Ono Pharmaceutical Co | Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki |
| WO2008108736A1 (en) | 2007-03-06 | 2008-09-12 | Agency For Science, Technology And Research | Particles for delivery of bioactive factors |
| US20110059172A1 (en) | 2008-01-29 | 2011-03-10 | Arthur Tzianabos | Therapeutic compositions |
| US8642333B2 (en) | 2008-02-04 | 2014-02-04 | Massachusetts Institute Of Technology | Particulate delivery vehicles for embryoid bodies |
| US20090297621A1 (en) * | 2008-06-03 | 2009-12-03 | Abbott Cardiovascular Systems Inc. | Microparticles For The Treatment Of Disease |
| GB0814302D0 (en) | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
-
2008
- 2008-08-05 GB GBGB0814302.6A patent/GB0814302D0/en not_active Ceased
-
2009
- 2009-08-05 EP EP09781530.2A patent/EP2323626B1/en active Active
- 2009-08-05 ES ES09781530.2T patent/ES2677005T3/es active Active
- 2009-08-05 MX MX2011001261A patent/MX2011001261A/es active IP Right Grant
- 2009-08-05 KR KR1020117004837A patent/KR101639827B1/ko not_active Expired - Fee Related
- 2009-08-05 CA CA2732785A patent/CA2732785C/en active Active
- 2009-08-05 WO PCT/EP2009/060171 patent/WO2010015665A2/en not_active Ceased
- 2009-08-05 CN CN2009801391387A patent/CN102170868A/zh active Pending
- 2009-08-05 AU AU2009279086A patent/AU2009279086B2/en not_active Ceased
- 2009-08-05 JP JP2011521575A patent/JP5623400B2/ja not_active Expired - Fee Related
- 2009-08-05 BR BRPI0917571-7A patent/BRPI0917571B1/pt not_active IP Right Cessation
-
2011
- 2011-02-04 CL CL2011000244A patent/CL2011000244A1/es unknown
-
2012
- 2012-03-20 US US13/425,041 patent/US20120195939A1/en not_active Abandoned
-
2013
- 2013-01-08 US US13/736,267 patent/US20130189321A1/en not_active Abandoned
- 2013-04-30 US US13/873,812 patent/US8846099B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529946A5 (cg-RX-API-DMAC7.html) | ||
| Bakhshandeh et al. | Recent progress in the manipulation of biochemical and biophysical cues for engineering functional tissues | |
| Batista et al. | Alginate: pharmaceutical and medical applications | |
| Yang et al. | Promotion of skin regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic fibroblast growth factor | |
| Patel et al. | Potential application of PLGA microsphere for tissue engineering | |
| US6596296B1 (en) | Drug releasing biodegradable fiber implant | |
| US20110268776A1 (en) | Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration | |
| US8062654B2 (en) | Drug releasing biodegradable fiber for delivery of therapeutics | |
| Rambhia et al. | Controlled drug release for tissue engineering | |
| US20130045266A1 (en) | Method for preparing polymeric biomaterials having immobilized drug delivery system comprising bioactive molecules loaded particle carrier | |
| WO2009131752A2 (en) | Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration | |
| Formiga et al. | Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration | |
| CN1961974B (zh) | 可生物降解及吸收的聚合物纳米纤维膜材料及其制备方法和用途 | |
| US20110027188A1 (en) | Methods, Compositions and Devices for Treating Lesioned Sites Using Bioabsorbable Carriers | |
| Ma et al. | Enhanced osteogenic activity and bone repair ability of PLGA/MBG scaffolds doped with ZIF-8 nanoparticles loaded with BMP-2 | |
| Wang et al. | Electrospun multifunctional tissue engineering scaffolds | |
| CN105407931A (zh) | 伤口敷料及其应用 | |
| CN102711798A (zh) | 刺激干细胞的药物组合物 | |
| CN102170868A (zh) | 包含介于10和20微米之间直径的微球的胃肠外给药组合物 | |
| Shen et al. | Growth factor loading on aliphatic polyester scaffolds | |
| Karim Haidar et al. | Nanofibers: new insights for drug delivery and tissue engineering | |
| US20240366734A1 (en) | Pharmaceutical composition for treating keloid and uses thereof | |
| JP2013512877A5 (cg-RX-API-DMAC7.html) | ||
| US9937232B2 (en) | Particles containing a growth factor, and uses thereof | |
| WO2018000082A2 (en) | Encapsulation-free controlled protein release system |